Phase 2 Recurrent Glioblastoma Clinical Trials
22 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 22 trials
Recruiting
Phase 1Phase 2
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 1Phase 2
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 1Phase 2
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 2
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
BioNTech SE75 enrolled6 locationsNCT07297212
Recruiting
Phase 2
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Recurrent Glioblastoma
Duke University80 enrolled4 locationsNCT06069726
Recruiting
Phase 2
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled324 locationsNCT06325683
Recruiting
Phase 2
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Glioblastoma, IDH-wildtypeRecurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype+6 more
Mayo Clinic36 enrolled1 locationNCT07301268
Recruiting
Phase 2
Sacituzumab Govitecan in Recurrent Glioblastoma
Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio32 enrolled3 locationsNCT04559230
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Recurrent Glioblastoma Multiforme (GBM)
Jecho Biopharmaceuticals Co., Ltd.40 enrolled1 locationNCT07501559
Recruiting
Phase 2
Surgical Pembro +/- Olaparib w TMZ for rGBM
GlioblastomaRecurrent Glioblastoma
L. Nicolas Gonzalez Castro, MD, PhD78 enrolled4 locationsNCT05463848
Recruiting
Phase 2
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Metastatic CancerLeptomeningeal MetastasisBrain Cancer+2 more
Memorial Sloan Kettering Cancer Center30 enrolled1 locationNCT06058988
Recruiting
Phase 1Phase 2
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-Wildtype
Tasly Pharmaceutical Group Co., Ltd26 enrolled1 locationNCT07318818
Recruiting
Phase 2
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaHigh Grade Astrocytic Tumor
Mayo Clinic54 enrolled1 locationNCT05465954
Recruiting
Phase 2
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
Recurrent Glioblastoma
University of Florida20 enrolled1 locationNCT06558214
Not Yet Recruiting
Phase 2
A study in participants with glioblastoma that has progressed after standard of care therapy, looking at the safety and effect of treatment with the experimental drug E-EDV-Dox/GC or EnGeneIC Dream Vectors (EDVs) packaged with the chemotherapy (Doxorubicin) given simultaneously with non-targeted EDVs carrying an immune enhancer called EDV-GC. (EDV-GBM Trial)
Recurrent Glioblastoma
EnGeneIC Pty Ltd30 enrolled3 locationsACTRN12625000779471
Recruiting
Phase 2
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.20 enrolled1 locationNCT06598787
Recruiting
Phase 1Phase 2
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
GlioblastomaRecurrent Glioblastoma
Emory University24 enrolled1 locationNCT04590664
Recruiting
Phase 2
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Recurrent GlioblastomaRecurrent WHO Grade 4 Glioma
Academic and Community Cancer Research United134 enrolled3 locationsNCT06160206
Recruiting
Phase 2
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
Recurrent Glioblastoma
Fifth Affiliated Hospital, Sun Yat-Sen University20 enrolled1 locationNCT06220552